Home / Business and Economy / Obesity Drug Race Heats Up: Lilly's New Pill Challenges Rivals
Obesity Drug Race Heats Up: Lilly's New Pill Challenges Rivals
2 Apr
Summary
- Eli Lilly's Foundayo targets the $200 billion obesity market.
- Drugmakers are acquiring novel therapies in a multi-billion dollar spree.
- Rising healthcare costs challenge affordability for patients and governments.
The pharmaceutical sector is witnessing a wave of strategic acquisitions, with major players like Eli Lilly, Biogen, and Novartis investing billions in novel drug pipelines. Eli Lilly's recent acquisition of Centessa for $7.8 billion and Biogen's $5.6 billion deal for Apellis Pharmaceuticals highlight this trend. Meanwhile, the highly lucrative obesity market, projected to reach $200 billion by 2030, is intensifying. Eli Lilly's new oral medication, Foundayo, has received swift US approval, positioning it as a competitor to Novo Nordisk's Wegovy. While Foundayo offers convenience, initial data suggests it may trail Wegovy slightly in weight loss.
Despite significant business growth and investment, the rising costs of healthcare present a substantial challenge for patients and governments worldwide. Germany is exploring cost-saving measures, and in the US, enrollment in Affordable Care Act plans has decreased due to escalating prices. This creates difficult choices for individuals struggling to afford essential medications. Innovations continue, with companies like Whoop raising significant funds for fitness tracking technology and further developments in obesity treatments being pursued by various biotech firms.
